Drug Combination Details
| General Information of the Combination (ID: C26342) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Gemigliptin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Type 2 diabetes mellitus
[ICD-11: 5A11]
|
Phase 1 | [1] | ||
|
Thyroid cancer
[ICD-11: 2D10]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | TPC-1 | CVCL_6298 | Thyroid gland papillary carcinoma | Homo sapiens | ||
| SW1736 | CVCL_3883 | Thyroid gland anaplastic carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells. | |||||
